PYXS
PYXS
NASDAQ · Biotechnology

Pyxis Oncology Inc

$1.27
-0.04 (-3.05%)
As of Mar 30, 10:09 PM ET ·
Financial Highlights (FY 2026)
Revenue
16.99M
Net Income
-81,375,709
Gross Margin
97.1%
Profit Margin
-479.0%
Rev Growth
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 97.1% 50.2% 50.2% 50.2%
Operating Margin -554.1% -29.7% -26.7% -27.8%
Profit Margin -479.0% -29.2% -26.4% -22.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 16.99M 59.72M 61.79M 57.95M
Gross Profit 16.49M 29.95M 30.99M 29.07M
Operating Income -94,155,918 -17,718,696 -16,524,048 -16,125,975
Net Income -81,375,709 -17,457,928 -16,293,891 -13,275,510
Gross Margin 97.1% 50.2% 50.2% 50.2%
Operating Margin -554.1% -29.7% -26.7% -27.8%
Profit Margin -479.0% -29.2% -26.4% -22.9%
Rev Growth -4.4% +5.4% +21.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 34.9K 9.30M 10.88M 8.95M
Total Equity 43.63M 30.51M 34.64M 32.57M
D/E Ratio 0.00 0.30 0.31 0.27
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -82,212,161 -19,228,267 -21,164,861 -19,065,899
Free Cash Flow -18,637,383 -17,592,445 -15,576,212